Eledon Pharmaceuticals, Inc. - Common Stock (ELDN)
4.5200
-0.1800 (-3.83%)
Eledon Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for the treatment of serious diseases through advancing the understanding of the immune system
The company is primarily engaged in creating and commercializing novel therapeutics that aim to enhance immune responses, with a strong emphasis on addressing unmet medical needs in areas such as neuromuscular and autoimmune disorders. By leveraging its proprietary platform, Eledon seeks to provide groundbreaking solutions that improve patient outcomes and transform healthcare in the specialties it targets.
Eledon Pharmaceuticals' results from islet cell transplant trial for type 1 diabetes, with tegoprubart showing safety and efficacy in kidney transplant patients. Analysts anticipate significant advancements, reflecting in raised price targets.
Eledon Pharmaceuticals announces successful use of tegoprubart in kidney xenotransplant. Promising results show its potential to prevent rejection, marking a significant milestone in organ transplantation research.
Gainers Airspan Networks Holdings Inc. (NYSEMIMO) shares rose 58.9% to $0.3754 in pre-market trading. Airspan Networks recently reported new financing and leadership changes.
Gainers Metacrine (NASDAQMTCR) shares rose 13.8% to $0.54 during Tuesday's after-market session. This security traded at a volume of 3.0 million shares come close, making up 948.6% of its average volume over the last 100 days. The company's market cap stands at $22.7 million.
